Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
2009 · BMC Urology · 90 citations
https://doi.org/10.1186/1471-2490-9-6
G
Giuseppe Gullo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
97
Papers
1.0K
Citations
17
h-index
24
i10-index
Giuseppe Gullo is an academic researcher from Regeneron (United States). The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies. The author has an h-index of 17, co-authored 83 publications.
ORCID: 0000-0001-5325-1055Papers by this author
worksMDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.
2007 · PubMed · 61 citations
Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
2012 · Annals of Oncology · 53 citations
https://doi.org/10.1093/annonc/mds221
Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature
2017 · Critical Reviews in Oncology/Hematology · 44 citations
https://doi.org/10.1016/j.critrevonc.2017.03.013
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
2018 · Investigational New Drugs · 29 citations
https://doi.org/10.1007/s10637-018-0649-y
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project
2018 · British Journal of Cancer · 17 citations
https://doi.org/10.1038/s41416-018-0114-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat